• 100+

    The UK’s most active investor in UK university spin-outs

  • £300M

    Over £300m raised; invested into over 100 companies

  • 17 wins

    Award winning manager with track record of delivering returns

  • £1.2Bn

    Part of FTSE 250 sector specialist group with £1.2bn net assets

About Parkwalk

Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.

Covid-19 Update: We continue to operate as usual, supporting the best of our technology companies. We accept applications by email and are having video updates with investors and advisers. Further details here.

Performance

We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.

Learn More

Meet the Parkwalk team

Combining our diverse range of skills and experience with integrity and transparency the Parkwalk team has an outstanding track record for supporting high-growth innovation that delivers returns.

Claire Pardo
Olivia Goodchild
Chloe Woodacre
Meet the team

Empowering Innovation

Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.

Sphere Fluidics

Sphere Fluidics picodroplet technology makes it possible to encapsulate and screen millions of individual cells or biological molecules in a single day. Its CytoMine proprietary microfluidic technology allows the ultra-high throughput analysis of isolated cells and generation of their genetic, transcriptomic and proteomic profiles in miniaturised (pL to nL) picodroplets. 

Azul Optics Limited

The company is developing novel, easy-to-use and affordable ophthalmic instruments utilising polarised light technology. The first focus is on screening people for low macular pigment density, which is an early predictor of age-related macular degeneration (AMD). AMD is a serious problem for upwards of 150m people worldwide and it cannot be cured. There are simple

Healthera

Healthera has developed a platform technology that enables patients to use the power of their mobile device to monitor and schedule their medicine use, and to stay in contact with their local pharmacy for advice and other services. For pharmacies, the patient-centric platform offers enhanced patient satisfaction and retention.

View Portfolio